Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05740007 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
A Phase 2 study, sponsored by Ironwood Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT05740007 is a Phase 2 study that was terminated before completion, run by Ironwood Pharmaceuticals. The registered enrollment target is 98 participants.
The verdict
NCT05740007, a Phase 2 study, was terminated before completion, sponsored by Ironwood Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The main question the study aims to answer is whether IW-3300 helps bladder pain and other symptoms (for example, bladder burning, pressure and discomfort). Subjects will be assigned to receive either the study drug or placebo by chance.
Interventions
- DRUG Placebo
- DRUG IW-3300 rectal foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2023-03-28 |
| Est. Completion | 2025-02-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05740007
The ClinicalTrials.gov registry entry for NCT05740007 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05740007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05740007 about?
NCT05740007 is a clinical study titled "A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome". The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The main question the study aims to answer is whether IW-3300 helps bladder pain and other symptoms (for example, bladder burning, pressure and discomfort)....
What is the current status of trial NCT05740007?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2023-03-28. Estimated completion is 2025-02-06.
What interventions are being tested in trial NCT05740007?
The interventions under investigation include: Placebo (DRUG), IW-3300 rectal foam (DRUG).
Who is sponsoring clinical trial NCT05740007?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.